CHA Healthcare incorporates Singapore's SMG as subsidiary

The company expanded its stake from 42.4% to 64.2%, building a medical network in the Asia-Pacific region

CHA Healthcare incorporates Singapore's SMG as subsidiary
Woo-Sang Lee 1
2024-08-19 17:15:59 idol@hankyung.com
Bio & Pharma



South Korea's CHA Healthcare Co., CHA Biotech's overseas medical business affiliate incorporated Singapore's SMG as a subsidiary.

CHA Healthcare announced on Monday that it incorporated Singapore Medical Group (SMG), which operates 46 specialty clinics across three Southeast Asian countries, as a subsidiary.

With SMG's performance in CHA Healthcare's consolidated financial statements from September this year, the company expects an increase in revenue and operating profit.

CHA Healthcare's consolidated revenue last year was 701.2 billion won ($527 million).

SMG, established in 2005, is the largest specialty clinic group in Southeast Asia. It operates specialty clinics such as women's health, obstetrics and gynecology, cancer treatment, radiology, pediatrics, and cosmetic dermatology, primarily in Singapore, and in major cities in Indonesia and Vietnam.

CHA Healthcare began strategic equity investment in SMG in 2017 and became the largest shareholder in 2019 by securing a 24% stake. In 2023, it increased its stake to 42.4% and recently expanded it to 64.2%.

Following CHA Healthcare's investment, SMG expanded its clinics from 30 to 46, showing steady growth. Revenue increased from 68 million Singapore dollars ($51.9 million) in 2017 to 123 million Singapore dollars ($93.9 million) in 2023.

EBITDA also grew from 13 million Singapore dollars ($9.9 million) to 23 million Singapore dollars ($17.6 million) over the same period.

CHA Healthcare operates over 70 global healthcare platforms and services in six countries, including the US, Australia, and Japan.

Write to Woo-Sang Lee at idol@hankyung.com
#CHA Healthcare #CHA Biotech #Singapore Medical Group #SMG #specialty clinics

Korea’s sole foreign clinic operator CHA Healthcare to go public in 2025

Korea’s sole foreign clinic operator CHA Healthcare to go public in 2025

CHA Hollywood Presbyterian Medical Center in Los Angeles, CA (Courtesy of CHA Healthcare) CHA Healthcare Co. operating nearly 90 hospitals and infertility treatment centers across the world, is set to pave the way for South Koreans' investment in foreign hospitals as it restarts the process to

Cha Biotech sells eye-cell technology to Japan's Astellas for $32 mn

Cha Biotech sells eye-cell technology to Japan's Astellas for $32 mn

Cha Biotech, a South Korean biotechnology company, said on Thursday that it agreed to sell its technology for developing eye-cell therapies to Astellas Regenerative Medicine Center, a US-based unit of Japan’s Astellas Pharma Inc., for $32 million.The deal involves the transfer of Cha Bio

Korea's Cha Bio Group to expand overseas real estate business

Korea's Cha Bio Group to expand overseas real estate business

Cha Bio Group, consisting of Cha Biotech and Cha Vaccine Research Institute as its subsidiaries, has announced its expansion into the real estate investment business. The South Korean health and biomedicine group has signed a business agreement with an asset management company IGIS Asset Manag

CHA Healthcare buys major Australian fertility center

CHA Healthcare buys major Australian fertility center

A newborn baby (Courtesy of Getty Images) South Korea’s medical center operator CHA Healthcare Co. said on Monday it has acquired the management rights of Fertility Specialists of Western Australia (FSWA), a major fertility center in Western Australia. CHA Healthcare made the deal via its

Korea’s CHA Biotech to triple US CDMO capacity

Korea’s CHA Biotech to triple US CDMO capacity

CHA Biotech CEO Oh Sang-hoon explains the production of cell therapies at the company’s research center in South Korea. CHA Biotech, South Korea’s stem cell therapeutics developer, is set to expand its biomaterials contract development and manufacturing organization (CDMO) business.
(* comment hide *}